Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-Label Study of Alfimeprase for Occluded Central Venous Access Devices
2006-000545-19Phase 2Completed
- Sponsor
- Nuvelo
- Start
- Apr 2006
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alfimeprase in catheter occlusion and Central venous access device withdrawal occlusion (PWO), sponsored by Nuvelo. Primary endpoints: Safety profile up to 120 minutes after alfimeprase instillation and Efficacy of alfimeprase in restoring catheter function. Started Apr 2006; status: completed.
02
Drugs
alfimeprase
03
Conditions
catheter occlusionCentral venous access device withdrawal occlusion (PWO)
Beyond the preview
Go deeper on 2006-000545-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000545-19.